Clinical TrialJul 30, 2026, 05:31 PM
Glucotrack's Lokahi Advances LT-100 to Single-Injection Clinical Trial
AI Summary
Glucotrack's wholly-owned subsidiary, Lōkahi Therapeutics Inc., announced significant progress in its LT-100 development strategy. The company aims to simplify the drug's administration from up to 15 intradermal injections to a single subcutaneous injection per visit. Following a Type C meeting with the FDA in May 2026 and a successful nonclinical minipig study, Lōkahi plans to initiate clinical evaluation of this simplified approach as early as the fourth quarter of 2026, with initial results expected in the first half of 2027.
Key Highlights
- Lōkahi Therapeutics is advancing its LT-100 development to simplify administration from 15 intradermal injections to a single subcutaneous injection.
- A Type C meeting with the FDA in May 2026 discussed the proposed clinical strategy for LT-100.
- A nonclinical minipig study confirmed systemic exposure consistency for subcutaneous administration.
- Clinical evaluation of the single-injection approach is expected to begin as early as Q4 2026.
- Initial clinical readout for the simplified administration is anticipated during the first half of 2027.
Price Impact
More from GCTK